This small-cap company made a 10-year agreement with a leading European company!

Management expects potential annual revenue of approximately Rs 40 crore.

Supriya Lifescience Limited entered into a long-term supply and sales agreement on May 23, 2023, with a prominent European company. This agreement entails the supply of Active Pharmaceutical Ingredients (API) for a duration of 10 years. Anticipated business prospects indicate a potential annual revenue of approximately Rs 40 crore at its peak, with the highest volumes expected to occur in FY27. It is noteworthy that Supriya Lifescience has secured an exclusive position as the sole supplier of this API.  

On Thursday, share price of Supriya Lifescience plunged by 1.08 per cent to Rs 256.3 apiece. It made an intraday high of Rs 264.7 and an intraday low of Rs 255.   

DSIJ offers a service 'Tiny Treasure' with recommendations for Small-Cap stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the product details pdf here

Supriya Lifescience specializes in the production of active pharmaceutical ingredients (APIs). The company has a comprehensive portfolio of 38 APIs, covering a wide range of therapeutic segments, including antihistamines, analgesics, anesthetics, vitamins, anti-asthmatics and anti-allergics.  

The company has achieved a notable 1 month return of 17.94 per cent, showcasing its strong performance in the short term. Additionally, it has delivered an impressive 3-month return of 28 per cent, further demonstrating its excellent performance over a slightly longer timeframe.  

Investors should keep this stock under their radar.